Treatment of older patients with mantle-cell lymphoma

H C Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, C H Geisler, S Stilgenbauer, C Thieblemont, U Vehling-Kaiser, J K Doorduijn, B Coiffier, R Forstpointner, H Tilly, L Kanz, P Feugier, M Szymczyk, M Hallek, S Kremers, G Lepeu, L SanhesJ M Zijlstra, R Bouabdallah, P J Lugtenburg, M Macro, M Pfreundschuh, V Procházka, F Di Raimondo, V Ribrag, M Uppenkamp, M André, W Klapper, W Hiddemann, M Unterhalt, M H Dreyling

    455 Citationer (Scopus)

    Abstract

    The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.
    OriginalsprogEngelsk
    TidsskriftNew England Journal of Medicine
    Vol/bind367
    Udgave nummer6
    Sider (fra-til)520-31
    Antal sider12
    ISSN0028-4793
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Treatment of older patients with mantle-cell lymphoma'. Sammen danner de et unikt fingeraftryk.

    Citationsformater